It is an honor to announce the 11th Annual Cholangiocarcinoma Foundation Conference. With Drs. Angela Lamarca, Mitesh J. Borad, and Do-Youn Oh as co-chairs, this promises to be a remarkable event. Dynamic sessions will provide a deeper detailing of the patient journey and matching with specific clinical trials. This year, we are offering a dedicated basic sciences track on Wednesday of the Conference.

One of the most unique and fulfilling part of the CCF Annual Conference is the interaction between the research community, providers, patients, and caregivers and we know this year will provide even more meaningful collaboration as part of that. Please register today and we look forward to seeing you in April.

Angela Lamarca, MD, PhD, MSc

Dr. Angela Lamarca is a medical oncologist who specializes in gastrointestinal malignancies (hepato-pancreato-biliary (HPB) and neuroendocrine tumors (NETs). She completed her training in Medical Oncology at the Hospital Universitario La Paz, Madrid. She moved to The Christie NHS Foundation Trust in 2013, where she completed a fellowship programme in HPB and NETs. 

She was awarded an American Society of Clinical Oncology Conquer Cancer Foundation Young Investigator Award in 2017 and in 2018, she was appointed as a Consultant in Medical Oncology at The Christie where she continues her Clinical and Translational Research career in HPB and NETs. Her aim is to achieve a better understanding of pancreatic, biliary tract cancer, and NET malignancies and to identify new treatment strategies for improving patients’ outcomes.

Mitesh J. Borad, MD

Dr. Borad received his MD from Rutgers New Jersey Medical School, completed internal medicine training at Cedars-Sinai, medical oncology training at Tulane University, and was a Genomics Medicine and Drug Development Scholar at TGen under the tutelage of Dr. Daniel Von Hoff. 

He is a Professor of Medicine, Program Leader for the Gene and Virus Therapy Program, and Director of the Precision Cancer Therapeutics Program at Mayo Clinic. He also serves on the NIH Drug Discovery and Pharmacology (DMP) Study Section as a Standing Member, NIH Hepatobiliary Cancer Task Force, and Board Member of the International Cholangiocarcinoma Research Network (ICRN). His research is focused on the development of novel therapeutics in the liver, biliary and pancreatic cancers by leveraging Next-gen whole genome sequencing approaches, as well as the application of emerging areas, such as the use of recombinant viruses with oncolytic/immunotherapeutic properties.


Do-Youn Oh, MD, PhD

Dr. Do-Youn Oh graduated from Seoul National University College of Medicine, and had residency training in Internal Medicine, and fellowship of Hematology/Medical Oncology training in Seoul National University Hospital. She earned her Ph.D Degree in the Department of Internal Medicine, Seoul National University College of Medicine and since 2006, she has been working as a Professor in Seoul National University Hospital.

Her main research interest is gastric cancer, pancreatic cancer and biliary tract cancer with particular interest in translational research and early drug development. She is involved in memberships in the medical society, including Korean Cancer Association, Korean Association of Clinical Oncology, Korean Cancer Study Group, American Society of Clinical Oncology and American Association for Cancer Research.


Wednesday: Patient and Caregiver Day and New Basic Sciences TrackWednesday is dedicated to patients and caregivers. Presentations on the most frequently asked topics, such as treatments, nutrition, side effects, and clinical trials, will be presented in a patient-friendly manner.

Wednesday: Basic Science Track
New this year will be a basic science track for researchers and scientists.

Thursday: Scientific Day
Thursday is geared towards the scientific and medical community. Renowned experts in the field will present the latest advances in research, clinical advancements, and treatment options. Attendees will have the opportunity to engage with our speakers through live Q&A sessions, interactive breakout sessions, and networking events.

Friday: Scientific Day
Continuing the scientific focus, Friday offers more in-depth insights into the latest developments in cholangiocarcinoma research and treatment. Explore breakthroughs, case studies, and emerging therapies, contributing to our collective knowledge and progress in combating this disease.


Wednesday, April 17, 2024, is Patient Day!

Don’t forget to pack something green to wear in support of all cholangiocarcinoma patients for the wear green contest.

You can also order a 2024 conference T-shirt to wear on Wednesday!


Your registration gives you access to the conference agenda and accompanying materials. Everyone who registers for the in-person experience gets a free swag bag







Young Investigator & Patient Advocate Organization


General Admission

$400 Early Bird until Jan 31, 2024

$500 after Jan 31, 2024



General Admission

$100 Early Bird until Jan 31, 2024

$150 after Jan 31, 2024

Patients, Caregivers & Young Investigators


Basic Science Chairs

Sumera I. Ilyas, MBBS

Sumera I. Ilyas, MBBS, is an Associate Professor of Medicine at the Mayo Clinic College of Medicine and Science. She is a physician-scientist who underwent training in internal medicine at the University of Pittsburgh Medical Center and subsequently completed Gastroenterology and Transplant Hepatology fellowships at the Mayo Clinic, Rochester. Her academic focus is hepatobiliary neoplasia. She is the director of the Mayo Clinic Hepatobiliary Neoplasia Clinic. She has an NIH-funded laboratory program focused on the immunobiology of cholangiocarcinoma and the development of combination immune-directed therapies for treating cholangiocarcinoma.

Daniela Sia, PhD

Daniela Sia, PhD, is an Assistant Professor in the Division of Liver Diseases, Department of Medicine, at Icahn School of Medicine at Mount Sinai in New York (US). Dr. Sia is a cancer biologist with a long-standing interest in understanding the molecular basis driving hepatobiliary cancers and translating this information into more effective therapeutic strategies. During her scientific career, Dr. Sia has contributed to elucidating the genomic landscape of cholangiocarcinoma, both intrahepatic and extrahepatic, and established the first immunogenomic classification of hepatocellular carcinoma. Furthermore, she identified a novel targetable FGFR2 fusion protein, FGFR2-PPHLN1, in ~15% of intrahepatic CCA. The current goal of the Sia laboratory is to develop new treatment paradigms for clinically relevant molecular subsets of cholangiocarcinoma using genomic analyses and patient-derived and animal models.


Salt Palace Convention Center

The conference will be held at the Salt Palace Convention Center located in downtown Salt Lake City, Utah. 

Salt Palace Convention Center
90 S W Temple St,
Salt Lake City, UT 84101

You will enter on the east side of the building at the "Salt Shaker" on S West Temple Drive, directly across the street from the Marriott Downtown at City Creek.


An overflow block has been secured at the AC Hotel in Salt Lake City Downtown at the rate of $229 per night (plus taxes and fees). 

CCF has secured a block of rooms at a discounted group room rate of $199 plus tax, based on availability. The deadline to book at this discounted rate is March 24, 2024. Tuesday, Wednesday and Thursday Nights are SOLD OUT. Shoulder Nights are still available

A stay at 4-star Salt Lake Marriott Downtown at City Creek places you in the heart of Salt Lake City, steps from Utah Museum of Contemporary Art and Salt Palace.

Enjoy recreation amenities such as a 24-hour fitness center or take in the view from a terrace. This hotel also features complimentary wireless Internet access, concierge services, and gift shops/newsstands.


Discounted Airport Transportation for Conference Attendees

Canyon Transportation is offering a special rate for CCF Attendees of $36.00 (before gratuity) for a round-trip to and from the Marriott City Creek. This rate is only available through the weblink and is not hosted by Cholangiocarcinoma Foundation.